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Abstract:  
A series of twenty two novel 1-cyclopropyl-6-fluoro-4-oxo-7-(4-substitutedpiperazin-1-yl)-
1,4-dihydroquinoline-3-carboxylic acid analogues have been synthesized, characterized (1H 
NMR, 13C NMR and LCMS) and evaluated for their inhibitory activity on the proliferation of 
human caucasian acute lymphoblastic leukemiacells (CCRF-CEM), breast adenocarcinoma cells 
(MDA-MB-468) and human colon carcinoma cells (HCT-116). Among all the synthesized 
ciprofloxacin analogues 3t at 50 µM showed comparable potency to doxorubicin (10µmol) in all 
three cell lines and 3j inhibited proliferation of MDA-MB-468 up to 35% selectively over other 
two cell lines. Cancer is a leading cause of death worldwide. It is a group of diseases 
characterized by uncontrolled growth. Cancer is the second cause of death in the US.1 
 
Ciprofloxacin (CP) is one of the broad-spectrum fluoroquinolone (FQ) antibiotics with low 
side effects.2CP exhibited antiproliferative and apoptotic activities in several cancer cell lines 
such as hormone resistant prostate cancer (HRPC) cell line (PC-3)3, transitional cell carcinoma 
cell lines (MBT-2 and T24)4, colon carcinoma cell lines (CC-531,SW-403 and HT-29)5, human 
lymphoidal cell lines (Jurkat)6, non-small-cell lung cancer cell line (NCI-H460 and A549)7,8, 
ovarian cancer cell line (CHO AA8)9, murine glioma cell line (GL26)10, bladder cell line 
(HTB9). CP was also found to exhibit cell cycle arrest at the S/G2-M checkpoints.11 
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Along with CP, other FQ derivatives like ofloxacin, levofloxacin, enoxacin and fleroxacin 
were shown to inhibit the growth of transitional cell and bladder carcinoma cell lines.2 CP 
enhanced the antiproliferative effect of 5-fluorouracil12, used for treatment of colon cancer.13 
FQs inhibit the activity of mammalian DNA topoisomerases I, II and DNA polymerase enzymes 
involved in supercoiling, transcription, replication and chromosomal separation of prokaryotic 
DNA.5,14 
Many reports indicate, antitumor efficacy of FQs can be augmented by increasing the 
lipophilicity of compounds.2,15,16 Introducing substituents at C-7 position of camptothecin 
improved the lipophilicity and this led to the discovery of gimatecan, which is currently in phase 
II clinical trials.17 In bis-quinolinium compounds, lipophilicity of the substituent enhanced their 
antiproliferative activity against HT-29 colon cancer cell line.18 Structure of FQ derivatives as 
anticancer agents is depicted in figure 1. 19-21 
CP showed antiproliferative and apoptotic activities on prostate cancer cell lines (PC3) but 
not on non-tumorigenic prostate epithelial cells (MLC8891).22CP can impede the acute and 
chronic prostate inflammation which is responsible for prostate cancer development.23 Fruitful 
anticancer results of lipophilic derivatives of CP have attracted us to investigate new lipophilic 
derivatives of CP as antitumor agents. Hence, we impelled our research work and synthesized 
new FQ derivatives as antitumor agents. In the current study, we synthesized 7-(substituted 
piperazin-1-yl) derivatives of CP. Firstly, 7-(4-(2-chloroacetyl)piperazin-1-yl)-1-cyclopropyl-6-
fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid(2)was synthesized by coupling CP with 
chloroacetyl chloride as reported earlier2 and then various substituted piperazines were reacted 
with 2 to enhance the lipophilicity (Scheme 1).  
Acylation of CP, 1 with chloroacetyl chloride in CH2Cl2 yielded compound 2 in 70% after 
purification.2 The series of 1-cyclopropyl-6-fluoro-4-oxo-7-(4-substituted piperazin-1-yl)-1,4-
dihydro quinoline-3-carboxylic acid derivativesof CP were prepared by coupling commercially 
available substituted piperazines with 2 in N,N-dimethylformamide (DMF) to obtain the final 
compounds 3a-v in yields ranging from 55- 95%.24(Scheme 1, Table 1) 
The synthesized compounds were evaluated for their inhibitory activity on the proliferation 
of three cancer cell lines vizhuman caucasian acute lymphoblastic leukemiacells (CCRF-CEM), 
breast adenocarcinoma cells (MDA-MB-468) and human colon carcinoma cells (HCT-116).  
Doxorubicin (Dox) and DMSO were used as positive and negative controls, respectively. The 
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results for the antiproliferative activity of the synthesized ciprofloxacin analogues 3a-v at 50 µM 
after 72 h incubation are shown in Figure 2. Most of the synthesized CP analogues were not as 
effective as positive controlin inhibiting the proliferation of these cell lines after 72 hincubation. 
Among all the CP analogues,3j inhibited proliferation of MDA-MB-468 up to 35% and 
compounds3s and3t with fluoro substituent inhibited proliferation of all three cancer cell lines in 
the range of 35-60%.3t at 50 µM showed comparable potency to doxorubicin (10 µmol) in all 
three cell lines. 
 
In summary, twenty two novel CP analogues were synthesized emphasizing on lipophilicity over 
two steps and evaluated for their anticancer activity on human caucasian acute lymphoblastic 
leukemiacells (CCRF-CEM), breast adenocarcinoma cells (MDA-MB-468) and human colon 
carcinoma cells (HCT-116). Among the synthesized ciprofloxacin analogues, 3t (fluoro 
substituent) at 50 µM showed comparable potency to doxorubicin (10 µmol) in all three cell 
lines, while 3j (without fluoro substituent) inhibited proliferation of MDA-MB-468 up to 35% 
selectively over other two cell lines. These results reveal the importance of fluoro substituent and 
further modification on the chemical structure of CP derivatives could lead to the synthesis of a 
promising candidate to develop anti-cancer agent. 
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Figure 1. Structures of somefluoro
 
Figure 2: Antiproliferative activity of compound 
 
Scheme 1: Synthesis of ciprofloxacin derivatives 
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Reagents and conditions: (a) Et3N,ClCH2COCl,CH2Cl2,0
0
C-RT; (b) Et3N,KI, substituted piperazines, 
150
0
C. 
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1. General: 
           All reagents were purchased from commercial available sources and used without further 
purification. CP was purchased from Sigma Aldrich (>98%). All reactions were monitored by 
analytical Thin Layer Chromatography (TLC) performed on E-Merck 0.25 mm pre coated silica 
gel glass plates (60 F254) using mixture of dichloromethane and methanol. Visualization of the 
spots on TLC plates was achieved either by exposure to UV light or by dipping the plates in 
ninhydrin solution and heating the plates at 1200C. Column chromatography was performed 
using silica gel (Acme, 100-200mesh). Solvents were dried according to conventional methods 
and purified by distillation prior to use. Solvents for chromatography (dichloromethane and 
methanol) were distilled prior to use. Evaporations were carried out under reduced pressure on 
Buchi rotary evaporator below 40-450C. Melting points were obtained using Stuart SMP30 
system and are uncorrected. Infrared (IR) spectra were recorded in KBr pellets on Schimadzu IR 
Prestige-21 FT-IR spectrophotometer (cm-1). 1H and 13C NMR spectra were recorded on 
Avance 300 (300.132 MHz for 1H, 100.61 MHz for 13C), in CDCl3 or DMSO-d6. Chemical 
shifts have been expressed in parts per million (δ) relative to tetramethylsilane (δ = 0.0) as an 
internal standard and coupling constants (J) in Hertz. Low-resolution mass spectra (ESI-MS) 
were recorded on Shimadzu. 
2. Cell Culture and Cell Proliferation Assay: 
 Cell Culture:    Human caucasian acute lymphoblastic leukaemiacells (CCRF-CEM), breast 
adenocarcinoma (MDA-MB-468) and human colon carcinoma cells (HCT-116) were obtained 
from American type culture collection. Cells were grown on 75 cm2 cell culture flasks with 
EMEM (Eagle’s minimum essential medium), supplemented with 10% fetal bovine serum, and 
1% penicillin/streptomycin solution (10,000 units of penicillin and 10 mg of streptomycin in 
0.9% NaCl) in a humidified atmosphere of 5% CO2, 95% air at 37 ºC. 
 
Cell Proliferation Assay:Cell proliferation assay was carried out using CellTiter 96 aqueous one 
solution cell proliferation assay kit (Promega, USA). Briefly, upon reaching about 75-80% 
confluency, 5000 cells/well were plated in 96-well microplate in 100 EL media. After seeding 
for 72 h, the cells were treated with 50 µM compound in triplicate. Doxorubicin (10 µM) was 
used as the positive control. At the end of the sample exposure period (72 h), 20 µL CellTiter 96 
aqueous solution was added. The plate was returned to the incubator for 1 h in a humidified 
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atmosphere at 37 °C. The absorbance of the formazan product was measured at 490 nm using 
microplate reader. The blank control was recorded by measuring the absorbance at 490 nm with 
wells containing medium mixed with CellTiter 96 aqueous solution but no cells. Results were 
expressed as the percentage of the control (without compound set at 100%). 
 
3.Physical and spectral data for 3b-v 
7-[4-(2-{4-(4-chlorophenyl)piperazin-1-yl}acetyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (3b) 
m.p. 249-250°C; 1H NMR (300 MHz, DMSO-D6) δ 1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 2H, J = 6.9 
Hz), 2.67 (m, 4H), 2.98 (m, 4H), 3.26 (m, 4H), 3.32 (m, 2H), 3.67 (m, 4H), 3.79 (tt, 1H, J = 7.2 
Hz, J = 6.9 Hz), 6.52 (d, 2H, J = 8.5 Hz), 7.1 (d, 2H, J = 5.8 Hz), 7.52 (d, 1H, JH-F = 7.5 Hz), 
7.89 (d, 1H, JH-F = 13.2 Hz), 8.63 (s, 1H), 15.18 (s, 1H). 13C NMR (100.61 MHz, CDCl3) δ 
176.82 (d, JC-F = 2.2 Hz), 167.56, 166.43, 153.21 (d, JC-F = 249.3 Hz), 147.84, 147.23, 145.12 (d, 
JC-F = 10.3 Hz), 138.95, 132.57, 125.51, 119.91 (d, JC-F = 8.1 Hz), 116.38, 111.97 (d, JC-F = 
24.14 Hz), 107.12, 104.89 (d, JC-F = 3.7 Hz), 53.89, 51.12, 50.46, 49.12, 45.84, 35.82, 8.43.  ESI-
MS (m/z): calcd. for C29H31ClFN5O4 567.20, found 568.29 [M + H]+. 
 
 7-[4-(2-{4-acetylpiperazin-1-yl}acetyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (3c) 
m.p. 230-231°C; 1H NMR (300 MHz, DMSO-D6) δ 1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 2H, J = 6.9 
Hz), 2.15 (s, 3H), 2.52 (m, 4H), 2.86 (m, 4H), 3.21 (m, 4H), 3.31 (m, 2H), 3.76 (m, 4H), 3.82 (tt, 
1H, J = 7.2 Hz, J = 6.9 Hz), 7.52 (d, 1H, JH-F = 7.5 Hz), 7.89 (d, 1H, JH-F = 13.2 Hz), 8.63 (s, 
1H), 15.18 (s, 1H). 13C NMR (100.61 MHz, CDCl3) δ 176.82 (d, JC-F = 2.2 Hz), 168.39, 167.56, 
153.21 (d, JC-F = 249.3 Hz), 147.23, 145.12 (d, JC-F = 10.3 Hz), 138.95, 119.91 (d, JC-F = 8.1 Hz), 
111.97 (d, JC-F = 24.14 Hz), 107.12, 104.89 (d,  JC-F = 3.7 Hz), 62.45, 52.83, 51.15, 48.86, 35.81, 
25.14, 8.17. ESI-MS (m/z): calcd. for C25H30FN5O5 499.22, found 500.42[M + H]+. 
 
 
 
 7-[4-(2-{4-benzylpiperazin-1-yl}acetyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (3d) 
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m.p. 104-106°C; 1H NMR (300 MHz, DMSO-D6) δ 1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 2H, J = 6.9 
Hz), 2.72 (m, 4H), 2.93 (m, 4H), 3.15 (s, 2H), 3.32 (m, 4H), 3.46 (m, 2H), 3.62 (m, 4H), 3.71 (tt, 
1H, J = 7.2 Hz, J = 6.9 Hz),  7.3 (m, 5H), 7.52 (d, 1H, JH-F = 7.5 Hz), 7.89 (d, 1H, JH-F = 13.2 
Hz), 8.63 (s, 1H), 15.18 (s, 1H). 13C NMR (100.61 MHz, CDCl3) δ 177.02 (d, JC-F = 2.2 Hz), 
168.33, 153.6 (d, JC-F = 249.3 Hz), 146.21, 145.49 (d, JC-F = 10.3 Hz), 139.01, 127.12, 126.75, 
126.13, 120.15 (d, JC-F = 8.1 Hz), 112.51 (d, JC-F = 24.14 Hz), 108.16, 105.08 (d, JC-F = 3.7 Hz), 
61.41, 54.31, 51.17, 51.48, 49.11, 45.07, 35.12, 8.65. ESI-MS (m/z): calcd. for C30H34FN5O4 
547.26, found 548.62 [M + H]+. 
 
1-cyclopropyl-6-fluoro-4-oxo-7-[4-(2-{4-phenylpiperazin-1-yl}acetyl)piperazin-1-yl]-1,4-
dihydroquinoline-3-carboxylic acid (3e) 
m.p. 212-214°C; 1H NMR (300 MHz, DMSO-D6) δ 1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 2H, J = 6.9 
Hz), 2.62 (m, 4H), 2.91 (m, 4H), 3.28 (m, 4H), 3.44 (m, 2H), 3.68 (m, 4H), 3.81 (tt, 1H, J = 7.2 
Hz, J = 6.9 Hz), 7.23 (m, 5H), 7.52 (d, 1H, JH-F = 7.5 Hz), 7.89 (d, 1H, JH-F = 13.2 Hz), 8.63 (s, 
1H), 15.18 (s, 1H). 13C NMR (100.61 MHz, CDCl3) δ 177.02 (d, JC-F = 2.2 Hz), 168.33, 166.82, 
153.6 (d, JC-F = 249.3 Hz), 147.53, 145.49 (d, JC-F = 10.3 Hz), 144.21, 139.01, 130.09, 128.41, 
127.74, 120.15 (d, JC-F = 8.1 Hz), 112.51 (d, JC-F = 24.14 Hz), 108.16, 105.08 (d, JC-F = 3.7 Hz), 
54.65, 52.42, 51.17, 49.33, 45.40, 34.86, 8.18. ESI-MS (m/z): calcd. for C29H32FN5O4 533.24, 
found 534.31 [M + H]+. 
 
7-[4-(2-{4-(2-chlorophenyl)piperazin-1-yl}acetyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (3f) 
m.p. 138-139 °C; 1H NMR (300 MHz, DMSO-D6) δ 1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 2H, J = 6.9 
Hz), 2.56 (m, 4H), 2.82 (m, 4H), 3.18 (m, 4H), 3.37 (m, 2H), 3.72 (m, 4H), 3.76 (tt, 1H, J = 7.2 
Hz, J = 6.9 Hz), 7.05 (t, 1H), 7.13 (d, 1H), 7.55 (m, 2H), 7.52 (d, 1H, JH-F = 7.5 Hz), 7.89 (d, 1H, 
JH-F = 13.2 Hz), 8.63 (s, 1H), 15.18 (s, 1H). 13C NMR (100.61 MHz, CDCl3) δ 177.02 (d, JC-F = 
2.2 Hz), 168.33, 166.82, 153.6 (d, JC-F = 249.3 Hz), 147.53, 145.49 (d, JC-F = 10.3 Hz), 143.84, 
139.01, 130.95, 129.13, 128.64, 124.2, 122.26, 120.15 (d, JC-F = 8.1 Hz), 112.51 (d, JC-F = 24.14 
Hz), 108.16, 105.08 (d, JC-F = 3.7 Hz), 53.11, 51.75, 50.83, 48.96, 44.72, 35.42, 7.87. ESI-MS 
(m/z): calcd. for C29H31ClFN5O4 567.20, found 568.35 [M + H]+. 
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7-[4-(2-{4-(4-cyanophenyl)piperazin-1-yl}acetyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (3g) 
m.p. 278-279°C; 1H NMR (300 MHz, DMSO-D6) δ 1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 2H, J = 6.9 
Hz), 2.45 (m, 4H), 2.79 (m, 4H), 3.21 (m, 4H), 3.32 (m, 2H), 3.67 (m, 4H), 3.71 (tt, 1H, J = 7.2 
Hz, J = 6.9 Hz), 6.65 (d, 2H, J = 8.5 Hz), 7.3 (d, 2H, J = 5.8 Hz), 7.52 (d, 1H, JH-F = 7.5 Hz), 
7.89 (d, 1H, JH-F = 13.2 Hz), 8.63 (s, 1H), 15.18 (s, 1H). 13C NMR (100.61 MHz, CDCl3) δ 
176.82 (d, JC-F = 2.2 Hz), 167.56, 166.43, 153.21 (d, JC-F = 249.3 Hz), 147.84, 147.23, 145.12 (d, 
JC-F = 10.3 Hz), 138.95, 131.86, 126.93, 119.91 (d, JC-F = 8.1 Hz), 117.12, 116.91, 111.97 (d, JC-F 
= 24.14 Hz), 107.12, 104.89 (d, JC-F = 3.7 Hz),  53.43, 51.75, 50.22, 49.72, 45.89, 35.23, 7.13. 
ESI-MS (m/z): calcd. for C30H31FN6O4 558.24, found 559.38 [M + H]+. 
 
1-cyclopropyl-6-fluoro-7-[4-(2-{4-(4-nitrophenyl)piperazin-1-yl}acetyl)piperazin-1-yl]-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (3h) 
m.p. 242-244°C; 1H NMR (300 MHz, DMSO-D6) δ1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 2H, J = 6.9 
Hz),2.54 (m, 4H), 2.83 (m, 4H), 3.23 (m, 4H), 3.38 (m, 2H), 3.69 (m, 4H), 3.79 (tt, 1H, J = 7.2 
Hz, J = 6.9 Hz), 6.7 (d, 2H, J = 8.5 Hz), 7.9 (d, 2H, J = 5.8 Hz), 7.52 (d, 1H, JH-F = 7.5 Hz), 7.89 
(d, 1H, JH-F = 13.2 Hz), 8.63 (s, 1H), 15.18 (s, 1H).13C NMR (CDCl3, 100 MHz) δ 176.82 (d, JC-F 
= 2.2 Hz), 167.56, 166.43, 153.21 (d, JC-F = 249.3 Hz), 148.42, 146.93, 145.12 (d, JC-F = 10.3 
Hz), 138.95, 132.45, 128.41, 119.91 (d, JC-F = 8.1 Hz), 117.12, 116.91, 111.97 (d, JC-F = 24.14 
Hz), 107.12, 104.89 (d, JC-F = 3.7 Hz), 53.39, 51.52, 50.79, 49.23, 35.85, 8.34. ESI-MS 
(m/z):calcd. for C29H31FN6O6 578.23, found 579.32 [M + H]+. 
 
1-cyclopropyl-6-fluoro-7-[4-(2-{4-(3-methoxyphenyl)piperazin-1-yl}acetyl)piperazin-1-yl]-4-oxo-
1,4-dihydroquinoline-3-carboxylicacid (3i) 
m.p. 144-145°C; 1H NMR (300 MHz, DMSO-D6) δ1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 2H, J = 6.9 
Hz),2.41 (m, 4H), 2.72 (m, 4H), 3.14 (m, 4H), 3.46 (m, 2H), 3.69 (m, 4H), 3.76 (s, 3H),  3.79 (tt, 
1H, J = 7.2 Hz, J = 6.9 Hz), 6.42 (d, 1H), 6.5 (s, 1H), 6.57 (d, 1H), 7.15 (t, 1H), 7.52 (d, 1H, JH-F 
= 7.5 Hz), 7.89 (d, 1H, JH-F = 13.2 Hz), 8.63 (s, 1H), 15.18 (s, 1H).13C NMR (CDCl3, 100 MHz) 
δ 177.02 (d, JC-F = 2.2 Hz), 168.33, 166.82, 153.6 (d, JC-F = 249.3 Hz), 146.27, 145.49 (d, JC-F = 
10.3 Hz), 144.56, 139.01, 131.29, 129.72, 129.13, 123.18, 120.15 (d, JC-F = 8.1 Hz), 112.51 (d, 
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JC-F = 24.14 Hz), 110.3, 108.16, 105.08 (d, JC-F= 3.7 Hz), 53.85, 52.11, 51.73, 48.17, 46.14, 
44.72,  35.42, 8.18. ESI-MS (m/z):calcd. for C30H34FN5O5 563.25, found 564.42 [M + H]+. 
 
7-[4-(2-{4-benzhydrylpiperazin-1-yl}acetyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (3j) 
m.p. 199-200°C; 1H NMR (300 MHz, DMSO-D6) δ1.20 (t, 2H, J = 7.2 Hz), 1.32 (t, 2H, J = 6.9 
Hz), 2.43 (m, 4H), 2.68 (m, 4H), 2.96 (s, 3H), 3.18 (m, 4H), 3.48 (m, 2H), 3.72 (m, 4H), 3.83 (tt, 
1H, J = 7.2 Hz, J = 6.9 Hz), 4.12 (s, 1H), 7.25 (m, 10H), 7.52 (d, 1H, JH-F = 7.5 Hz), 7.89 (d, 1H, 
JH-F = 13.2 Hz), 8.63 (s, 1H), 15.18 (s, 1H).13C NMR (100.61 MHz, CDCl3) δ 177.02 (d, JC-F = 
2.2 Hz), 168.33, 166.82, 153.6 (d, JC-F = 249.3 Hz), 147.53, 145.49 (d, JC-F = 10.3 Hz), 142.60, 
139.01, 128.52, 127.86, 127.00, 120.15 (d, JC-F = 8.1 Hz), 112.51 (d, JC-F = 24.14 Hz), 108.16, 
105.08 (d, JC-F= 3.7 Hz), 76.27, 53.35, 51.92, 50.65, 49.45, 45.48, 35.33, 8.26. ESI-MS 
(m/z):calcd. for C36H38FN5O4 623.29, found 624.41 [M + H]+. 
 
1-cyclopropyl-6-fluoro-4-oxo-7-[4-(2-{4-m-tolylpiperazin-1-yl}acetyl)piperazin-1-yl]-1,4-
dihydroquinoline-3-carboxylicacid (3k) 
m.p. 158-160°C; 1H NMR (300 MHz, DMSO-D6) δ1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 2H, J = 6.9 
Hz), 2.19 (s, 3H), 2.38 (m, 4H), 2.66 (m, 4H), 3.38 (m, 4H), 3.41 (m, 2H), 3.72 (m, 4H), 3.76 (tt, 
1H, J = 7.2 Hz, J = 6.9 Hz), 6.55 (d, 1H), 6.68 (d, 1H), 6.71 (s, 1H), 7.04 (t, 1H), 7.52 (d, 1H, JH-
F = 7.5 Hz), 7.89 (d, 1H, JH-F = 13.2 Hz), 8.63 (s, 1H), 15.18 (s, 1H).13C NMR (100.61 MHz, 
CDCl3) δ 177.02 (d, JC-F = 2.2 Hz), 168.33, 166.82, 153.6 (d, JC-F = 249.3 Hz), 146.03, 145.49 
(d, JC-F = 10.3 Hz), 141.48, 139.01, 129.5, 127.59, 127.11, 126.58, 122.34, 120.15 (d, JC-F = 8.1 
Hz), 112.51 (d, JC-F = 24.14 Hz), 108.16, 105.08 (d, JC-F= 3.7 Hz), 53.87, 51.12, 50.86, 49.43, 
45.12, 35.39, 22.29, 8.18. ESI-MS (m/z):calcd. for C30H34FN5O4 547.26, found 548.39 [M + H]+. 
 
1-cyclopropyl-6-fluoro-4-oxo-7-[4-(2-{4-(1-phenylethyl)piperazin-1-yl}acetyl)piperazin-1-yl]-1,4-
dihydroquinoline-3-carboxylicacid (3l) 
m.p. 212-214°C; 1H NMR (300 MHz, DMSO-D6) δ1.18 (t, 2H, J = 7.2 Hz), 1.20 (d, 3H), 1.29 (t, 
2H, J = 6.9 Hz),2.39 (m, 4H), 2.52 (m, 4H), 3.06 (q, 1H), 3.31 (m, 4H), 3.38 (m, 2H), 3.64 (m, 
4H), 3.78 (tt, 1H, J = 7.2 Hz, J = 6.9 Hz), 7.3 (m, 5H), 7.52 (d, 1H, JH-F = 7.5 Hz), 7.89 (d, 1H, 
JH-F = 13.2 Hz), 8.63 (s, 1H), 15.18 (s, 1H).13C NMR (100.61 MHz, CDCl3) δ 177.02 (d, JC-F = 
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2.2 Hz), 168.33, 166.82, 153.6 (d, JC-F = 249.3 Hz), 147.53, 145.49 (d, JC-F = 10.3 Hz), 142.60, 
139.01, 128.52, 127.86, 127.00, 120.15 (d, JC-F = 8.1 Hz), 112.51 (d, JC-F = 24.14 Hz), 108.16, 
105.08 (d, JC-F= 3.7 Hz), 72.21, 54.11, 52.19, 51.07, 48.69, 46.18, 34.04, 22.67, 8.13. ESI-MS 
(m/z):calcd. for C31H36FN5O4 561.28, found 562.41 [M + H]+. 
 
1-cyclopropyl-7-[4-(2-{4-ethylpiperazin-1-yl}acetyl)piperazin-1-yl]-6-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylicacid (3m) 
m.p. 239-240°C; 1H NMR (300 MHz, DMSO-D6) δ1.08 (t, 3H), 1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 
2H, J = 6.9 Hz), 2.9 (q, 2H), 2.36 (m, 4H), 2.48 (m, 4H), 3.32 (m, 4H), 3.52 (m, 2H), 3.67 (m, 
4H), 3.79 (tt, 1H, J = 7.2 Hz, J = 6.9 Hz), 7.55 (d, 1H, JH-F = 7.5 Hz), 7.89 (d, 1H, JH-F = 13.2 
Hz), 8.63 (s, 1H), 15.18 (s, 1H).13C NMR (100.61 MHz, CDCl3) δ 176.82 (d, JC-F = 2.2 Hz), 
167.56, 166.43, 153.21 (d, JC-F = 249.3 Hz), 147.23, 145.12 (d, JC-F = 10.3 Hz), 138.95, 119.91 
(d, JC-F = 8.1 Hz), 111.97 (d, JC-F = 24.14 Hz), 107.12, 104.89 (d, JC-F = 3.7 Hz),  54.56, 52.23, 
51.67, 49.71, 48.87, 44.76, 34.74, 14.87, 8.45. ESI-MS (m/z):calcd. for C25H32FN5O4 485.24, 
found 486.37 [M + H]+. 
 
7-[4-(2-{4-(2-cyanophenyl)piperazin-1-yl}acetyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (3n) 
m.p. 222-223°C; 1H NMR (300 MHz, DMSO-D6) δ 1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 2H, J = 6.9 
Hz), 2.62 (m, 4H), 3.14 (m, 4H), 3.34 (m, 4H), 3.66 (m, 2H), 3.77 (m, 4H), 3.82 (tt, 1H, J = 7.2 
Hz, J = 6.9 Hz), 7.05 (t, 1H), 7.13 (d, 1H), 7.55 (m, 2H), 7.66 (d, 1H, JH-F = 7.5 Hz), 7.92 (d, 1H, 
JH-F = 13.2 Hz), 8.63 (s, 1H), 15.18 (s, 1H). 13C NMR (100.61 MHz, CDCl3) δ 176.82 (d, JC-F = 
2.2 Hz), 167.56, 166.43, 153.21 (d, JC-F = 249.3 Hz), 147.23, 145.12 (d, JC-F = 10.3 Hz), 142.43, 
138.95, 128.2, 127.43, 126.32, 122.78, 119.91 (d, JC-F = 8.1 Hz), 111.97 (d, JC-F = 24.14 Hz), 
108.23, 107.12, 104.89 (d, JC-F = 3.7 Hz), 81.42, 53.59, 51.12, 50.58, 49.33, 45.06,  35.99, 8.54. 
ESI-MS (m/z):calcd. for C30H31FN6O4 558.24, found 559.36 [M + H]+. 
 
 
1-cyclopropyl-6-fluoro-4-oxo-7-[4-(2- {4-(pyridine-2-yl)piperazin-1-yl}acetyl) piperazin-1-yl]- 1,4-
dihydroquinoline-3-carboxylic acid (3o) 
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m.p. 204-205°C; 1H NMR (300 MHz, DMSO-D6) δ 1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 2H, J = 6.9 
Hz), 2.57 (m, 4H), 3.23 (m, 4H), 3.31 (m, 4H), 3.56 (m, 2H), 3.61 (m, 4H), 3.77 (tt, 1H, J = 7.2 
Hz, J = 6.9 Hz), 7.16 (t, 1H), 7.21 (d, 1H), 7.62 (m, 2H), 7.66 (d, 1H, JH-F = 7.5 Hz), 7.92 (d, 1H, 
JH-F = 13.2 Hz), 8.63 (s, 1H), 15.18 (s, 1H). 13C NMR (100.61 MHz, CDCl3) δ 176.82 (d, JC-F = 
2.2 Hz), 167.56, 166.43, 154.34, 153.21 (d, JC-F = 249.3 Hz), 150.78, 148.43, 147.23, 146.07, 
145.12 (d, JC-F = 10.3 Hz), 138.95, 121.56, 119.91 (d, JC-F = 8.1 Hz), 111.97 (d, JC-F = 24.14 Hz), 
107.12, 104.89 (d, JC-F = 3.7 Hz), 53.78, 53.12, 50.96, 48.76, 45.78, 37.23, 8.45. ESI-MS 
(m/z):calcd. for C28H31FN6O4 534.24, found 535.36 [M + H]+. 
 
1-cyclopropyl-6-fluoro-4-oxo-7-[4-(2-{4-(pyrimidine-2-yl)piperazin-1-l}acetyl)piperazin- 1-yl]-1,4-
dihydroquinoline-3-carboxylicacid (3p) 
m.p. 189-190°C; 1H NMR (300 MHz, DMSO-D6) δ 1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 2H, J = 6.9 
Hz), 2.46 (m, 4H), 2.58 (m, 4H), 3.05 (m, 4H), 3.34 (m, 2H), 3.67 (m, 4H), 3.77 (tt, 1H, J = 7.2 
Hz, J = 6.9 Hz), 7.01(t, 1H), 7.55 (d, 1H, JH-F = 7.5 Hz), 7.89 (d, 1H, JH-F = 13.2 Hz), 8.31 (d, 
2H, J = 4.6 Hz), 8.63 (s, 1H), 15.18 (s, 1H). 13C NMR (100.61 MHz, CDCl3) δ 176.82 (d, JC-F = 
2.2 Hz), 167.56, 166.43, 160.67, 154.89, 153.21 (d, JC-F = 249.3 Hz), 147.23, 145.12 (d, JC-F = 
10.3 Hz), 138.95, 122.45, 119.91 (d, JC-F = 8.1 Hz), 111.97 (d, JC-F = 24.14 Hz), 107.12, 104.89 
(d, JC-F = 3.7 Hz), 54.12, 52.23, 51.08, 49.67, 44.97, 36.24, 8.14. ESI-MS (m/z):calcd. for 
C27H30FN7O4 535.23, found 536.39 [M + H]+. 
 
1-cyclopropyl-7-[4-(2-{4-(3,4-dimethoxyphenyl)piperazin-1-yl}acetyl)piperazin-1-yl]-6-fluoro-4-
oxo-1,4-dihydroquinoline-3-carboxylicacid (3q) 
m.p. 189-190°C; 1H NMR (300 MHz, DMSO-D6) δ 1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 2H, J = 6.9 
Hz), 2.35 (m, 4H), 2.42 (m, 4H), 3.25 (m, 4H), 3.38 (m, 2H), 3.71 (m, 4H), 3.73 (s, 6H), 3.79 (tt, 
1H, J = 7.2 Hz, J = 6.9 Hz), 6.25 (s, 1H), 6.56 (d, 1H), 6.63 (d, 1H), 7.55 (d, 1H, JH-F = 7.5 Hz), 
7.89 (d, 1H, JH-F = 13.2 Hz), 8.63 (s, 1H), 15.18 (s, 1H). 13C NMR (100.61 MHz, CDCl3) δ 
176.82 (d, JC-F = 2.2 Hz), 167.56, 166.43, 153.21 (d, JC-F = 249.3 Hz), 147.23, 145.12 (d, JC-F = 
10.3 Hz), 143.24, 140.67, 138.08, 138.95, 121.78, 116.02, 119.91 (d, JC-F = 8.1 Hz), 117.32, 
111.97 (d, JC-F= 24.14 Hz), 107.12, 104.89 (d, JC-F = 3.7 Hz), 61.45, 60.95, 59.34, 53.35, 51.92, 
50.65, 49.45, 35.33, 8.26. ESI-MS (m/z):calcd. for C31H36FN5O6 593.26, found 594.39 [M + H]+. 
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1-cyclopropyl-6-fluoro-7-[4-(2-{4-(3-hydroxyphenyl)piperazin-1-yl}acetylpiperazin-1-yl]-4-oxo-1,4-
dihydroquinoline-3-carboxylicacid (3r) 
m.p. 220-222°C; 1H NMR (300 MHz, DMSO-D6) δ 1.18 (t, 2H, J = 7.2 Hz), 1.29 (t, 2H, J = 6.9 
Hz), 2.32 (m, 4H), 2.43 (m, 4H), 3.34 (m, 4H), 3.46 (m, 2H), 3.67 (m, 4H), 3.81 (tt, 1H, J = 7.2 
Hz, J = 6.9 Hz), 5.23 (s, 1H), 6.39 (d, 1H), 6.45 (s, 1H), 6.52 (d, 1H), 7.05 (t, 1H), 7.52 (d, 1H, 
JH-F = 7.5 Hz), 7.89 (d, 1H, JH-F = 13.2 Hz), 8.63 (s, 1H), 15.18 (s, 1H). 13C NMR (100.61 MHz, 
CDCl3) δ 176.82 (d, JC-F = 2.2 Hz), 167.56, 166.43, 153.21 (d, JC-F = 249.3 Hz), 147.23, 146.58, 
145.12 (d, JC-F = 10.3 Hz), 142.03, 138.95, 134.61, 119.91 (d, JC-F = 8.1 Hz), 111.97 (d, JC-F = 
24.14 Hz), 107.28, 107.12, 106.07, 104.89 (d, JC-F = 3.7 Hz), 101.72,  54.15, 50.91, 51.27, 49.81, 
44.73, 35.99, 8.12. ESI-MS (m/z):calcd. for C29H32FN5O5 549.24, found 550.45 [M + H]+. 
 
1-cyclopropyl-7-[4-(2-{4-(3,4-difluorophenyl)piperazin-1-yl}acetyl)piperazin-1-yl]-6-fluoro-
4-oxo-1,4-dihydroquinoline-3-carboxylicacid (3s) 
m.p. 198-200°C; 1H NMR (300 MHz, DMSO-D6) δ 1.24 (t, 2H, J = 7.2 Hz), 1.37 (t, 2H, J = 6.9 
Hz), 2.32 (m, 4H), 2.56 (m, 4H), 3.35 (m, 4H), 3.39 (m, 2H), 3.79 (m, 4H), 3.85 (tt, 1H, J = 7.2 
Hz, J = 6.9 Hz), 6.98 (dd, 1H, JH-F = 7.1 Hz), 7.15 (dt, 1H, JH-F = 13.2 Hz, 6.8 Hz), 7.25 (dd, 1H, 
JH-F = 12.11 Hz, 7.01 Hz), 7.63 (d, 1H, JH-F = 7.5 Hz), 7.97 (d, 1H, JH-F = 13.2 Hz), 8.71 (s, 1H), 
15.22 (s, 1H).13C NMR (100.61 MHz, CDCl3) δ 176.82 (d, JC-F = 2.2 Hz), 167.56, 166.43, 
162.58 (dd, JC-F = 252.67 Hz, 22.68 Hz),153.21 (d, JC-F = 249.3 Hz), 151.52 (dd, JC-F = 247.28 
Hz, 21.39 Hz),147.23, 145.12 (d, JC-F = 10.3 Hz), 141.49 (d, JC-F = 2.8 Hz), 138.95, 125.23 (d, 
JC-F = 3.07 Hz), 119.91 (d, JC-F = 8.1 Hz), 111.97 (d, JC-F = 24.14 Hz), 110.87 (dd, JC-F = 23.81 
Hz, 3.7 Hz), 109.42 (dd, JC-F = 20.65 Hz, 2.95 Hz),  107.12, 104.89 (d, JC-F = 3.7 Hz), 55.32, 
51.49, 51.11, 49.72, 45.29, 35.37, 8.42. ESI-MS (m/z):calcd. for C29H30F3N5O4 569.22, found 
570.49 [M + H]+. 
 
 
 
7-[4-(2-{4-(bis(4-fluoroophenyl)methyl)piperazin-1-yl}acetyl)piperazin-1-yl]-1-cyclo propyl-6-
fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylicacid (3t) 
m.p. 195-196°C; 1H NMR (300 MHz, DMSO-D6) δ 1.19 (t, 2H, J = 7.2 Hz), 1.32 (t, 2H, J = 6.9 
Hz), 2.39 (m, 4H), 2.56 (m, 4H), 3.25 (m, 4H), 3.35 (m, 2H), 3.74 (m, 4H), 3.86 (tt, 1H, J = 7.2 
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Hz, J = 6.9 Hz), 4.2 (s, 1H), 7.13-7.21 (dd, 4H, JH-F = 8.5 Hz), 7.42-7.5 (dd, 4H, JH-F = 5.8 Hz, 
JH-F = 7.5 Hz) 7.59-7.61 (d, 1H, JH-F = 7.5 Hz), 7.94-7.99 (d, 1H, JH-F = 13.2 Hz), 8.71 (s, 1H), 
15.22 (s, 1H). 13C NMR (100.61 MHz, DMSO-D6) δ 176.97 (d, JC-F = 2.2 Hz), 168.23, 166.76, 
161.83 (d, JC-F = 246.49 Hz), 153.57 (d, JC-F = 251.52 Hz), 147.50, 145.45 (d, = 10.3 Hz), 
139.01, 138.07 (d, JC-F = 2.9 Hz), 129.21 (d, JC-F = 7.3 Hz), 120.08 (d, d, JC-F = 8.1 Hz), 115.43 
(d, JC-F= 21.27 Hz), 112.46 (d, JC-F = 23.48 Hz), 108.11, 105.05 (d, JC-F = 3.7 Hz), 74.43, 53.31, 
51.70, 50.61, 49.39, 45.45, 35.32, 8.25. ESI-MS (m/z):calcd. for C36H36F3N5O4 659.27, found 
660.62 [M + H]+. 
 
1-cyclopropyl-7-[4-(2-{4-(2-(dimethylamino)ethyl)piperazin-1-yl}acetyl)piperazin-1-yl]-6-fluoro-4-
oxo-1,4-dihydroquinoline-3-carboxylicacid (3u) 
m.p. 138-140°C; 1H NMR (300 MHz, DMSO-D6) δ 1.24 (t, 2H, J = 7.2 Hz), 1.37 (t, 2H, J = 6.9 
Hz), 2.42 (m, 4H), 2.59 (m, 4H), 2.70 (t, 4H), 2.83 (s, 6H ), 3.35 (m, 4H), 3.39 (m, 2H), 3.76 (m, 
4H), 3.89 (tt, 1H, J = 7.2 Hz, J = 6.9 Hz), 7.63 (d, 1H, JH-F = 7.5 Hz), 7.97 (d, 1H, JH-F = 13.2 
Hz), 8.71 (s, 1H), 15.22 (s, 1H). 13C NMR (100.61 MHz, CDCl3) δ 176.82 (d, JC-F = 2.2 Hz), 
167.56, 166.43, 153.21 (d, JC-F = 249.3 Hz), 147.23, 145.12 (d, JC-F = 10.3 Hz), 138.95, 119.91 
(d, JC-F = 8.1 Hz), 111.97 (d, JC-F = 24.14 Hz), 107.12, 104.89 (d, JC-F = 3.7 Hz), 60.95, 53.53, 
51.67, 50.22, 49.20, 48.63, 47.97, 41.11, 35.12, 8.09. ESI-MS (m/z):calcd. for C27H37FN6O4 
528.29, found 530.41 [M + H]+. 
 
1-cyclopropyl-6-fluoro-4-oxo-7-[4-(2-{4-(3-(trifluoromethyl)phenyl)piperazin-1-yl} 
acetyl)piperazin-1-yl]-1,4-dihydroquinoline-3-carboxylicacid (3v) 
m.p. 190-192°C; 1H NMR (300 MHz, DMSO-D6) δ 1.24 (t, 2H, J = 7.2 Hz), 1.37 (t, 2H, J = 6.9 
Hz), 2.42 (m, 4H), 2.59 (m, 4H), 3.35 (m, 4H), 3.39 (m, 2H), 3.76 (m, 4H), 3.89 (tt, 1H, J = 7.2 
Hz, J = 6.9 Hz), 7.14 (d, 1H, 7.78 Hz), 7.26 (s, 1H), 7.30 (d, 1H, 8.3 Hz), 7.48 (t, 1H, 8.03 Hz), 
7.63 (d, 1H, JH-F = 7.5 Hz), 7.97 (d, 1H, JH-F = 13.2 Hz), 8.71 (s, 1H), 15.22 (s, 1H). 13CNMR 
(100.61 MHz, CDCl3) δ 176.82 (d, JC-F = 2.2 Hz), 167.56, 166.43, 153.21 (d, JC-F = 249.3 Hz), 
148.38 (d, JC-F = 249.3 Hz), 147.23, 145.12 (d, JC-F = 10.3 Hz), 138.95, 132.94, 126.39, 124.62, 
119.91 (d, JC-F = 8.1 Hz), 119.19, 116.47, 112.72, 111.97 (d, JC-F = 24.14 Hz), 107.12, 104.89 (d, 
JC-F = 3.7 Hz), 54.11, 50.89, 50.16, 49.92, 45.14, 35.49, 8.08.  ESI-MS (m/z):calcd. for 
C30H31F4N5O4 601.23, found 602.56 [M + H]+ 
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